Makary leaves FDA after 13 months

The Food and Drug Administration just lost its commissioner again — and that matters because the FDA is the referee for drugs, devices, diagnostics, food safety, and a lot of lab products. Marty Makary resigned on May 12 after only about 13 months in the job, and Kyle Diamantas moved into the acting role. The immediate drama is personnel. The bigger issue is that the agency had already been wobbling. Now the wobble gets worse. ### Who left, exactly? Makary is a Johns Hopkins surgeon who took over the FDA in 2025 and quickly became one of the most visible faces of the administration’s health agenda. On Tuesday, multiple outlets reported that he resigned, and Trump publicly confirmed both the departure and Diamantas’ temporary promotion. That makes Diamantas — who had been serving as the FDA’s top food official — the acting head while the White House figures out a permanent replacement. (politico.com) ### Why did this happen now? The short version is that Makary’s position had been weakening for weeks. The reporting points to mounting frustration inside the White House, plus a long trail of complaints from political allies, industry factions, and advocacy groups that all wanted different things from the agency. This was not one bad day. It looks more like a commissioner who ran out of internal support. (cnbc.com) ### What were the biggest fights? One flashpoint was flavored vapes. Makary drew pressure over how quickly the FDA was moving on fruit-flavored e-cigarette applications, which had become a political issue as much as a public-health one. Other fights piled on — staffing cuts, leadership turnover, disputes over reproductive-health policy, and broader arguments over whether the agency was making decisions on evidence or on political demand. (politico.com) ### Why does staffing matter so much here? Because the FDA is not a one-person shop. A commissioner sets tone, but the real machinery runs through career scientists, reviewers, compliance staff, and center directors. Makary’s tenure was marked by mass layoffs and persistent churn among senior leaders. That is a bad mix for an agency that depends on institutional memory. Think of it like pulling managers and mechanics out of an air-traffic-control tower at the same time — planes may still land, but nobody feels calm about it. (politico.com) ### Why should companies care? Because FDA instability changes timelines even when no rule formally changes. Drugmakers, device firms, food companies, and suppliers of regulated lab products all make plans around review speed, enforcement posture, and who inside the agency can actually make decisions. When leadership flips and internal teams are unsettled, companies start gaming for delay, surprise reversals, or sudden priority shifts. That uncertainty can be as consequential as a new regulation. (politico.com) ### Is Diamantas just a placeholder? For now, yes — but acting leaders still matter. Diamantas had been handling food policy and serving as a liaison point between the FDA, HHS, and the White House. That means he is not walking in cold. But an acting commissioner usually governs with less political room than a Senate-confirmed one, especially when the agency is already dealing with factional fights and morale problems. (msn.com) ### What does this say about the FDA right now? Basically, the agency looks politically exposed. The FDA is supposed to be science-led, but the story around Makary’s exit is that scientific judgment kept colliding with ideological demands, business pressure, and White House impatience. Even if a new commissioner arrives quickly, the deeper problem does not disappear — people now have reason to wonder how durable any FDA decision really is. (msn.com) ### Bottom line? Makary’s resignation is not just a personnel change. It is a sign that the FDA’s chain of command is still unstable — and when the regulator is unstable, everyone it regulates has to brace for a rougher ride. (politico.com)